$484 Million is the total value of GREAT POINT PARTNERS LLC's 28 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 81.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MGNX | Buy | MACROGENICS INC | $42,998,000 | +51.8% | 1,350,000 | +8.9% | 8.89% | +93.1% |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $33,721,000 | -12.2% | 760,000 | +8.6% | 6.97% | +11.8% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $29,444,000 | -30.8% | 930,000 | +1.4% | 6.08% | -12.0% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $28,599,000 | -27.3% | 382,085 | -15.9% | 5.91% | -7.4% |
| XENT | Buy | INTERSECT ENT INC | $27,828,000 | -6.7% | 1,332,773 | +2.3% | 5.75% | +18.7% |
| EXEL | Buy | EXELIXIS INC | $27,133,000 | +184.6% | 1,201,100 | +152.9% | 5.61% | +262.3% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $26,162,000 | +14.9% | 156,406 | +4.3% | 5.41% | +46.2% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $26,082,000 | -1.6% | 375,870 | +8.9% | 5.39% | +25.1% |
| PODD | Buy | INSULET CORP | $23,378,000 | +52.4% | 89,600 | +49.3% | 4.83% | +94.0% |
| MRTX | New | MIRATI THERAPEUTICS INC | $23,126,000 | – | 135,000 | +100.0% | 4.78% | – |
| BIIB | New | BIOGEN INC | $20,981,000 | – | 75,000 | +100.0% | 4.34% | – |
| COLL | Buy | COLLEGIUM PHARMACEUTICAL INC | $20,415,000 | +141.9% | 861,410 | +104.4% | 4.22% | +207.7% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $20,406,000 | -30.9% | 872,415 | -14.9% | 4.22% | -12.0% |
| KDMN | Buy | KADMON HLDGS INC | $18,497,000 | +9.1% | 4,755,000 | +16.4% | 3.82% | +38.9% |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $16,525,000 | -6.8% | 1,007,012 | +17.6% | 3.42% | +18.6% |
| TVTX | New | TRAVERE THERAPEUTICS INC | $14,825,000 | – | 593,712 | +100.0% | 3.06% | – |
| LNTH | New | LANTHEUS HLDGS INC | $13,880,000 | – | 649,516 | +100.0% | 2.87% | – |
| PBYI | PUMA BIOTECHNOLOGY INC | $12,636,000 | -5.3% | 1,300,000 | 0.0% | 2.61% | +20.6% | |
| NVRO | New | NEVRO CORP | $11,160,000 | – | 80,000 | +100.0% | 2.31% | – |
| IFRX | New | INFLARX NV | $8,580,000 | – | 2,200,000 | +100.0% | 1.77% | – |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $8,029,000 | -79.2% | 311,217 | -56.8% | 1.66% | -73.5% |
| LUNG | Buy | PULMONX CORP | $5,230,000 | +17.8% | 114,345 | +77.7% | 1.08% | +49.9% |
| RDHL | New | REDHILL BIOPHARMA LTDsponsored ads | $5,163,000 | – | 705,305 | +100.0% | 1.07% | – |
| RXDX | New | PROMETHEUS BIOSCIENCES INC | $4,565,000 | – | 250,000 | +100.0% | 0.94% | – |
| YMAB | New | Y-MABS THERAPEUTICS INC | $4,536,000 | – | 150,000 | +100.0% | 0.94% | – |
| GERN | Sell | GERON CORP | $4,124,000 | -48.7% | 2,610,000 | -48.4% | 0.85% | -34.8% |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $3,983,000 | – | 502,900 | +100.0% | 0.82% | – |
| TCDA | New | TRICIDA INC | $1,849,000 | – | 349,600 | +100.0% | 0.38% | – |
| MLND | Exit | MILLENDO THERAPEUTICS INC | $0 | – | -270,000 | -100.0% | -0.09% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -175,000 | -100.0% | -0.39% | – |
| CALA | Exit | CALITHERA BIOSCIENCES INCcall | $0 | – | -500,000 | -100.0% | -0.40% | – |
| SBTX | Exit | SILVERBACK THERAPEUTICS INC | $0 | – | -70,000 | -100.0% | -0.53% | – |
| IONS | Exit | IONIS PHARMACEUTICALS INC | $0 | – | -75,000 | -100.0% | -0.69% | – |
| FGEN | Exit | FIBROGEN INCcall | $0 | – | -166,500 | -100.0% | -1.00% | – |
| FMTX | Exit | FORMA THERAPEUTICS HLDGS INC | $0 | – | -236,400 | -100.0% | -1.34% | – |
| CALA | Exit | CALITHERA BIOSCIENCES INC | $0 | – | -1,845,000 | -100.0% | -1.47% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -977,647 | -100.0% | -1.91% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -487,452 | -100.0% | -2.11% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -164,150 | -100.0% | -2.26% | – |
| TBPH | Exit | THERAVANCE BIOPHARMA INC | $0 | – | -824,580 | -100.0% | -2.38% | – |
| GBT | Exit | GLOBAL BLOOD THERAPEUTICS IN | $0 | – | -595,473 | -100.0% | -4.19% | – |
| VCEL | Exit | VERICEL CORP | $0 | – | -900,000 | -100.0% | -4.51% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -799,722 | -100.0% | -6.14% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -390,000 | -100.0% | -7.31% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.